Skip to main content
Quest Diagnostics

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Authors: Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, Meyer III WA, Kaufman HW, Anderson S, Cohen O, Petkov VI, Cronin KA, VanDyke AL, Lowy DR, Sharpless NE, Penberthy LT

Citation: JAMA Intern Med. 2021 Feb 24;e210366. doi: 10.1001/jamainternmed.2021.0366. Online ahead of print.

Specialties: COVID-19, Dermatology, Infectious Disease, Immunology

Download key summary

Related content

Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Test FAQ
SARS CoV 2 Antibody Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.